diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Intervention 1: Intervention group: pentoxifylline 400 mg daily for 12 week. Intervention 2: Control group: ?ncreasing dose of losartan 50 mg daily for 12 week.
Sponsors
National Institute for Medical Research Development
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: type2 diabetes according to American Diabetes Association (ADA 2019) with proteinuria
Exclusion criteria
Exclusion criteria: infectious or malignant diseases non-diabetic kidney disease retinal hemorrhage acute myocardial infarction or unstable angina history of cardio-cerbro-vascular or peripheral artery disease uncontrolled hypertension (i.e., systolic blood pressure [SBP] = 140mmHg and/or diastolic blood pressure [DBP] = 90 mmHg) pregnancy anemia hyperthyroidism history of hemodialysis baseline serum potassium concentrations =5.5 meq/L estimated glomerular filtration rate (eGFR) < 30mL/minute/1.73 m and pentoxifylline intolerance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resistin. Timepoint: before treatment and after 12 weeks. Method of measurement: Adiponectin will be measured using a quantitative sandwich ELISA.;Hs-CRP. Timepoint: before treatment and after 12 weeks. Method of measurement: hs-CRP will be measured using a quantitative sandwich ELISA.;TNFa. Timepoint: before treatment and after 12 weeks. Method of measurement: TNFa will be measured using a quantitative sandwich ELISA.;Copeptin. Timepoint: before treatment and after 12 weeks. Method of measurement: Copeptin will be measured using a quantitative sandwich ELISA immunoassay.;Osteopontin. Timepoint: before treatment and after 12 weeks. Method of measurement: Osteopontin will be measured using a quantitative sandwich ELISA.;Cystatin c. Timepoint: before treatment and after 12 weeks. Method of measurement: cystatin c will be measured using a quantitative sandwich ELISA.;HSP70. Timepoint: before treatment and after 12 weeks. Method of measurement: HSP70 will be measured using a quantitative sandwich ELISA.;Bilirubin. Timepoint: before treatment and after 12 weeks. Method of measurement: Bilirubin will be measured using an enzymatic assay.;Uric acid. Timepoint: before treatment and after 12 weeks. Method of measurement: Uric acid will be measured using an enzymatic assay.;Apo A. Timepoint: before treatment and after 12 weeks. Method of measurement: Apo A will be measured using a quantitative sandwich ELISA.;Apo B. Timepoint: before treatment and after 12 weeks. Method of measurement: Apo B will be measured using a quantitative sandwich ELISA.;Adiponectin. Timepoint: before treatment and after 12 weeks. Method of measurement: Adiponectin will be measured using a quantitative sandwich ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmanouchehr nakhjavani
Tehran University of Medical Sciences
Outcome results
None listed